Search

During a virtual awards ceremony, MSK and the Robbins Family Foundation recognized eight distinguished MSK staff members and one team for their exemplary service. Each member was honored with the 2021 Robbins Family Award for Nursing Excellence.

… Wednesday, May 12, 2021 Elizabeth McCormick, Senior Vice President, and Chief Nursing Executive Elizabeth McCormick, Senior Vice President, and Chief Nursing Executive MSK Nurses celebrate Nurses Week, May 6-12 MSK Nurses celebrate Nurses Week, May 6-12 MSK Nurses celebrate Nurses Week, May 6-12 MSK

Memorial Sloan Kettering Cancer Center (MSK) today announced that it has been awarded a Specialized Programs of Research Excellence (SPORE) grant for pancreatic research by the National Cancer Institute (NCI).

… Tuesday, October 11, 2022 Memorial Sloan Kettering Cancer Center (MSK) today announced that it has been awarded a Specialized Programs of Research Excellence (SPORE) grant for pancreatic research by the  National Cancer Institute (NCI) . The long-term goal of the grant is to demonstrate that prospective

Memorial Sloan Kettering’s 37th annual academic Convocation and the fifth Louis V. Gerstner Graduate School of Biomedical Sciences Commencement shared the spotlight on May 19.

… Tuesday, July 5, 2016 An afternoon ceremony on May 19 celebrated MSK’s 37th annual Convocation and the fifth Louis V. Gerstner Graduate School of Biomedical Sciences Commencement. Presided over by MSK President and CEO Craig Thompson , it recognized students who conducted their doctoral dissertation

Memorial Sloan Kettering Cancer Center (MSK), The Rockefeller University and Weill Cornell Medicine announced today that they have established a new drug discovery company called Bridge Medicines. Launched in partnership with Takeda Pharmaceutical Company Ltd. and healthcare investment firms Bay City Capital and Deerfield Management, Bridge Medicines is a groundbreaking initiative that completes a seamless, fully funded and professionally staffed path from concept to drug candidate to efficiently and rapidly develop innovative therapeutics for treating human diseases.

… Monday, October 31, 2016 Memorial Sloan Kettering Cancer Center, The Rockefeller University and Weill Cornell Medicine announced today that they have established a new drug discovery company called Bridge Medicines. Launched in partnership with Takeda Pharmaceutical Company Ltd. and healthcare investment

Learn how our donor community is supporting MSK research and education.

… Thursday, April 1, 2021 Every day, your dollars are accelerating today’s most daring discoveries straight into lifesaving care. Read more to learn about your impact. The Society of Memorial Sloan Kettering Winter Lunch On February 3, The Society of MSK hosted its eighth annual Winter Lunch to support

A prominent research grant will enable MSK doctors and scientists to advance the treatment of bladder cancer.

… Friday, May 31, 2019 Summary The National Cancer Institute recently awarded MSK a prestigious SPORE grant for bladder cancer research. Learn about how MSK researchers will use the $6.5 million award to gain insights into how the disease develops and responds to treatment. Bladder cancer is the fifth

Several types of cancer were once strongly linked to an AIDS diagnosis. Thanks to improved HIV medications, that's changing.

… Wednesday, April 3, 2019 Summary People with HIV are sometimes susceptible to getting specific types of cancer. This association has changed over the years, as drugs to control HIV infection have become available. When the AIDS epidemic began in 1981, many of the first reported cases were young gay men

A drug combination that halts tumor cell division can stir the immune system into taking action.

… Thursday, December 20, 2018 Summary According to scientists at the Sloan Kettering Institute, a two-drug combination that doesn’t directly kill tumor cells can still help as a cancer treatment. The key is activating the immune system. The goal of most cancer-fighting drugs is to kill tumor cells. But

In what is being hailed as a watershed moment for both cancer care and biotechnology, the US Food and Drug Administration has approved a personalized, cell-based immunotherapy for use in children and young adults with blood cancer. For more information or to arrange interviews, e-mail Caitlin Hool at [email protected].

… Tuesday, September 5, 2017 The FDA has approved a new type of immunotherapy called chimeric antigen receptor (CAR) T cell therapy . In this approach, scientists genetically engineer a patient’s own immune cells to make a new protein that can latch onto cancer. This turns them into supercharged cancer

A first-in-class allogeneic CAR T cell therapy regimen demonstrated feasibility and acceptable safety with preliminary evidence of efficacy in patients with heavily pretreated multiple myeloma, according to interim results from the phase 1 UNIVERSAL trial (NCT04093596) published recently in Nature Medicine.

… Wednesday, February 15, 2023 A first-in-class allogeneic CAR T cell therapy regimen demonstrated feasibility and acceptable safety with preliminary evidence of efficacy in patients with heavily pretreated multiple myeloma, according to interim results from the phase 1 UNIVERSAL trial ( NCT04093596 )